Bull case
Celldex Therapeutics is supported by barzolvolimab’s strong Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 results, where both studies met primary and key secondary endpoints and produced complete response rates of 42% to 46% at Week 12, deepening to 45% to 54% by Week 24. Physicians overwhelmingly viewed the therapy as more effective than current advanced options, with 81% calling it somewhat or much more effective, while the safety profile remained broadly consistent with prior data and showed only two probable anaphylaxis cases among more than 2,400 treated patients, a low incidence of about 0.08%. The company also has multiple upcoming catalysts, including Week 52 extension data, a 2027 BLA submission plan, and ongoing development in atopic dermatitis, cold urticaria, and symptomatic dermographism, supporting a differentiated mast-cell platform with meaningful commercial potential.